Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Schedule of Reconciliation of Net Loss to Net Loss Attributable to Heat Biologics, Inc.) (Details)

v3.10.0.1
Net Loss Per Share (Schedule of Reconciliation of Net Loss to Net Loss Attributable to Heat Biologics, Inc.) (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]        
Net loss $ (3,923,586) $ (2,504,178) $ (11,463,927) $ (9,053,987)
Net loss: Non-controlling interest (265,024) (203,371) (668,219) (344,328)
Net loss attributable to Heat Biologics, Inc. $ (3,658,562) $ (2,300,807) $ (10,795,708) $ (8,709,659)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc. - basic and diluted 23,143,952 3,578,661 14,359,429 3,269,536
Net loss per share attributable to Heat Biologics, Inc. - basic and diluted $ (0.16) $ (0.64) $ (0.75) $ (2.66)